Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Teewinot Secures U.S. Patent for Biosynthesis of Cannabinoids

By PR Newswire | January 10, 2017

Teewinot Life Sciences’ Irish subsidiary Full Spectrum Laboratories, Ltd. secures a new U.S. patent for biosynthesis of cannabinoids.

Teewinot Life Sciences Corporation’s Irish subsidiary, Full Spectrum Laboratories, Ltd. (FSL), was granted a U.S. patent entitled Chemical Engineering Processes and Apparatus for the Synthesis of Compounds. U.S. Patent No. 9,526,715 (“the ‘715 patent”) was granted on December 27, 2016.  The ‘715 patent claims are directed to biosynthetic processes for making cannabinoids.

Teewinot’s CEO Jeff Korentur stated “Our intent is to create disruption in the pharmaceutical cannabinoid manufacturing space.  We have demonstrated that these proprietary equipment and methods improve a wide range of API production metrics, and we look forward to partnering with customers that could benefit from these advantages.”

Teewinot’s Executive Vice President Dr. Richard Peet stated that “Teewinot’s Irish subsidiary, FSL, owns a rapidly expanding patent portfolio covering processes for manufacture of cannabinoids, cannabinoid prodrugs and cannabinoid analogs.  FSL’s patent portfolio also covers novel cannabinoid prodrugs, cannabinoid analogs and treatment therapies.  With federally licensed laboratories in Canada, an Irish subsidiary, and global headquarters in Tampa, Florida, Teewinot is well positioned to be a worldwide leader in the manufacture and delivery of cannabinoid-based therapies.”

(Source: PR Newswire)

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 


Filed Under: Drug Discovery

 

Related Articles Read More >

Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50